PL2076244T3 - Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanie - Google Patents
Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanieInfo
- Publication number
- PL2076244T3 PL2076244T3 PL07873522T PL07873522T PL2076244T3 PL 2076244 T3 PL2076244 T3 PL 2076244T3 PL 07873522 T PL07873522 T PL 07873522T PL 07873522 T PL07873522 T PL 07873522T PL 2076244 T3 PL2076244 T3 PL 2076244T3
- Authority
- PL
- Poland
- Prior art keywords
- lipid
- compositions
- preparation
- methods
- aqueous systems
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85044606P | 2006-10-10 | 2006-10-10 | |
US95702207P | 2007-08-21 | 2007-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2076244T3 true PL2076244T3 (pl) | 2017-05-31 |
Family
ID=39864519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07873522T PL2076244T3 (pl) | 2006-10-10 | 2007-10-10 | Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanie |
Country Status (10)
Country | Link |
---|---|
US (2) | US20160310600A1 (pl) |
EP (1) | EP2076244B1 (pl) |
JP (2) | JP5917789B2 (pl) |
CA (1) | CA2666322C (pl) |
DK (1) | DK2076244T3 (pl) |
ES (1) | ES2617747T3 (pl) |
HU (1) | HUE031951T2 (pl) |
PL (1) | PL2076244T3 (pl) |
PT (1) | PT2076244T (pl) |
WO (1) | WO2008127358A2 (pl) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090291134A1 (en) * | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
EP2101731B1 (en) | 2006-11-21 | 2018-01-31 | Jina Pharmaceuticals Inc. | Endoxifen for use in the treatment of cancer |
PT2344198T (pt) * | 2008-09-27 | 2020-12-04 | Jina Pharmaceuticals Inc | Preparações farmacêuticas à base de lípidos para aplicação tópica |
CA2765541A1 (en) | 2009-06-19 | 2010-12-23 | Sun Pharma Advanced Research Company Ltd. | Nanodispersion of a drug and process for its preparation |
US8591942B2 (en) * | 2009-09-23 | 2013-11-26 | Indu JAVERI | Methods for the preparation of liposomes comprising docetaxel |
US20170340563A1 (en) * | 2009-09-23 | 2017-11-30 | Curirx Inc. | Methods for the Preparation of Liposomes Comprising Drugs |
HUE032409T2 (en) | 2011-01-04 | 2017-09-28 | Archivel Farma Sl | Liposome preparation for treating or preventing tuberculosis |
PT2802345T (pt) | 2012-01-12 | 2018-04-24 | Archivel Farma Sl | Vacina mtb-c contra a asma |
US10220095B2 (en) | 2013-03-15 | 2019-03-05 | Taiwan Liposome Company, Ltd | Controlled drug release liposome compositions and methods thereof |
CN105682481A (zh) * | 2013-10-21 | 2016-06-15 | 酶学技术有限公司 | 包含胆碱及其衍生物的组合物、其用途以及其制备方法 |
RU2707748C2 (ru) | 2013-11-08 | 2019-11-29 | Активус Фарма Ко., Лтд. | Композиция водной суспензии, включающая наночастицы макролидных антибиотиков |
EP3150196A1 (en) * | 2015-09-30 | 2017-04-05 | Sun Pharma Advanced Research Company Ltd | Process for the preparation of unilamellar liposomal composition |
MY198105A (en) * | 2016-01-07 | 2023-08-02 | Univ Western Health Sciences | Formulations for treating bladder cancer |
WO2017177228A1 (en) | 2016-04-08 | 2017-10-12 | The Board Of Trustees Of The University Of Illinois | Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia |
US20170290852A1 (en) * | 2016-04-08 | 2017-10-12 | Wisconsin Alumni Research Foundation | Micelle formulations of amphotericin b |
US20200155583A1 (en) * | 2017-02-21 | 2020-05-21 | Ico Therapeutics Inc. | Solid oral formulations of amphotericin b |
US20190083386A1 (en) | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | Methods and formulations for transdermal administration of buffering agents |
WO2019106511A1 (en) * | 2017-11-30 | 2019-06-06 | Shilpa Medicare Limited | Composition of docetaxel liposomal injection with high drug loading |
EP3603682A1 (en) * | 2018-08-03 | 2020-02-05 | Alchilife S.r.l. | Tablet with an antimycotic agent, medical device and method for preserving harvested corneas |
US11857680B2 (en) * | 2018-11-26 | 2024-01-02 | Shilpa Medicare Limited | Composition of docetaxel liposomal injection with high drug loading |
US20230226002A1 (en) * | 2020-06-15 | 2023-07-20 | University Of Utah Research Foundation | Retinal bioavailbility of synthetic very-long-chain polyunsaturated fatty acids |
US20230357308A1 (en) * | 2020-10-12 | 2023-11-09 | Durect Corporation | Crystalline sodium cholesteryl sulfonate |
WO2022081481A2 (en) * | 2020-10-12 | 2022-04-21 | Durect Corporation | Crystalline sodium cholesteryl sulfate |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5782311A (en) * | 1980-11-11 | 1982-05-22 | Tanabe Seiyaku Co Ltd | Production of liposome preparation |
JPS5782310A (en) * | 1980-11-11 | 1982-05-22 | Tanabe Seiyaku Co Ltd | Production of liposome preparation |
JPS6058915A (ja) * | 1983-09-12 | 1985-04-05 | Fujisawa Pharmaceut Co Ltd | 薬物含有脂質小胞体製剤 |
US5084269A (en) * | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
KR0154343B1 (ko) * | 1990-11-06 | 1998-11-16 | 아만 히데아키 | 동결 건조 제제 및 이의 제조방법 |
DE4207481A1 (de) * | 1992-03-10 | 1993-09-16 | Bayer Ag | Liposomale wirkstoff-formulierungen und verfahren zu ihrer herstellung |
EP0792143B1 (en) * | 1994-11-18 | 2002-09-04 | Aphios Corporation | Methods for making liposomes containing hydrophobic drugs |
HUP0303719A2 (hu) * | 2000-10-16 | 2004-03-01 | Neopharm, Inc. | Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra |
CA2427467C (en) * | 2000-11-09 | 2010-01-12 | Neopharm, Inc. | Sn-38 lipid complexes and methods of use |
NZ537393A (en) * | 2002-06-11 | 2007-01-26 | Ethypharm Sa | Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
US20070213411A1 (en) * | 2003-11-05 | 2007-09-13 | The Australian National University | Dispersions And Methods Of Preparing Them |
US20060110441A1 (en) * | 2004-10-28 | 2006-05-25 | Harry Wong | Lyophilized liposome formulations and method |
-
2007
- 2007-10-10 EP EP07873522.2A patent/EP2076244B1/en active Active
- 2007-10-10 ES ES07873522.2T patent/ES2617747T3/es active Active
- 2007-10-10 JP JP2009532562A patent/JP5917789B2/ja active Active
- 2007-10-10 DK DK07873522.2T patent/DK2076244T3/en active
- 2007-10-10 PL PL07873522T patent/PL2076244T3/pl unknown
- 2007-10-10 CA CA2666322A patent/CA2666322C/en active Active
- 2007-10-10 WO PCT/US2007/080984 patent/WO2008127358A2/en active Application Filing
- 2007-10-10 PT PT78735222T patent/PT2076244T/pt unknown
- 2007-10-10 HU HUE07873522A patent/HUE031951T2/en unknown
-
2015
- 2015-10-02 JP JP2015196744A patent/JP2016041704A/ja active Pending
-
2016
- 2016-07-07 US US15/204,826 patent/US20160310600A1/en not_active Abandoned
-
2020
- 2020-07-09 US US16/924,529 patent/US20200345849A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2016041704A (ja) | 2016-03-31 |
WO2008127358A3 (en) | 2008-12-24 |
EP2076244A4 (en) | 2013-01-09 |
PT2076244T (pt) | 2017-03-09 |
EP2076244B1 (en) | 2016-12-07 |
CA2666322C (en) | 2013-04-23 |
US20160310600A1 (en) | 2016-10-27 |
ES2617747T3 (es) | 2017-06-19 |
CA2666322A1 (en) | 2008-10-23 |
JP5917789B2 (ja) | 2016-05-18 |
US20200345849A1 (en) | 2020-11-05 |
JP2010505965A (ja) | 2010-02-25 |
WO2008127358A2 (en) | 2008-10-23 |
HUE031951T2 (en) | 2017-08-28 |
EP2076244A2 (en) | 2009-07-08 |
DK2076244T3 (en) | 2017-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2076244T3 (pl) | Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanie | |
AU2007299727A8 (en) | Self preserved aqueous pharmaceutical compositions | |
IL193772A0 (en) | 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same | |
EP2130552A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-GRP78 ANTIBODY AS AN ACTIVE SUBSTANCE | |
EP2078731A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT | |
EP1841761A4 (en) | Fumagillol derivatives or processes for the preparation of fumagillol derivatives, and pharmaceutical compositions containing them | |
IL195488A (en) | Compounds, pharmaceuticals containing them and their uses | |
ZA200900347B (en) | Preparation of pharmaceutical compositions | |
IL196280A0 (en) | Use of ampk-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them | |
ZA200901702B (en) | Self-preserved aqueous pharmaceutical compositions | |
IL195528A (en) | Pyridazine compound, methods of preparation, a pharmaceutical composition containing it, its use and intermediate material | |
IL198847A0 (en) | New process for the preparation of 2-imino-thiazolidin-4-one derivatives | |
ME02689B (me) | Novi kristalni oblik iii agomelatina, postupak za njegovu pripremu i farmaceutski preparati istog | |
IL197877A (en) | Uses of aminomethyl-4-imidazole derivatives for the preparation of medications and medications containing them | |
IL194961A0 (en) | Compounds a-r-x for the manufacture of pharmaceutical preparations | |
IL213452A0 (en) | Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof | |
ZA201007610B (en) | Processes for the preparation of benzo-fused dioxin derivatives | |
HUP0600293A2 (en) | Zinc salt of rosuvastatine, process for its preparation and pharmaceutical compositions containing it | |
EP2193795A4 (en) | AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST | |
WO2008081268A3 (en) | Pharmaceutical compositions of entacapone | |
IL213474A0 (en) | Processes for the preparation of cyclopropyl-amide derivatives | |
ZA200901164B (en) | Self preserved aqueous pharmaceutical compositions | |
IL214028A (en) | A cyanopyrimidine or salt compound, a pharmaceutical preparation containing it, its use and an aqueous liquid containing the said pharmaceutical composition | |
HK1126190A1 (en) | Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them | |
IL190230A0 (en) | Derivatives of 2-aminthiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals |